Revolution Medicines: Benefit Vs Reality Compared To Peer Therapeutics (NASDAQ:RVMD)

· seekingalpha.com

Revolution Medicines has delivered a breakthrough with daraxonrasib in 2L pancreatic cancer doubling survival versus chemo. Read why RVMD stock is a hold.

Revolution Medicines ( RVMD ), or RevMed, is a US-listed Biotech co-founded and led by Third Rock partner Mark Goldsmith and team in collaboration with Universi...


Read on WOBR AI → · More AI market news · StrategyVerse · Quant Research · WOBR.AI